Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT04036448 Completed - Clinical trials for Myelodysplastic Syndromes

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

RevlimidPMS
Start date: August 18, 2019
Phase:
Study type: Observational

The Drug Use Examination (DUE) is planned and designed for the safety evaluation of new indications after the approval of a new drug in Korea. This DUE is a non-interventional, observational and post-marketing surveillance, which will be conducted by collecting the safety information of REVLIMID® for new indications in routine clinical practice in Korea. Six-Hundred (600) adult patients, who start with REVLIMID® treatment based on the approved local package insert (PI) of REVLIMID® during routine clinical practice in Korea and have indications noted below. 1. Patients with transfusion-dependent anemia due to IPSS low- or intermediate-1-risk Myelodysplastic Syndromes associated with a deletion 5q cytogenetic abnormality (del [5q] MDS) 2. Patients with mantle cell lymphoma who have received at least one prior therapy (rrMCL) 3. Previously treated follicular lymphoma (FL), in combination with rituximab (an anti-CD20 antibody)

NCT ID: NCT04036305 Enrolling by invitation - Anesthesia, Local Clinical Trials

Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers

Start date: July 26, 2019
Phase:
Study type: Observational

Local anesthetic resistance is commonly reported by patients with EDS. However, there are no objective data on the occurrence of local anesthetic resistance in EDS patients and in healthy volunteers. We propose to collect such objective data on the frequency of drug resistance and whether any problems with local anesthesia are due to initial ineffectiveness or due to its effects dissipating too soon.

NCT ID: NCT04036006 Completed - Metabolic Syndrome Clinical Trials

Enhanced Lifestyles for Metabolic Syndrome

ELM
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

This is a multi-center behavioral randomized trial with the aim of comparing a group-based lifestyle intervention with a self-directed lifestyle intervention on remission of the metabolic syndrome over 2 years of follow-up.

NCT ID: NCT04035668 Terminated - Sjögren Syndrome Clinical Trials

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

LOUiSSe
Start date: July 12, 2019
Phase: Phase 2
Study type: Interventional

This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome. LOU064 is an oral Bruton's tyrosine kinase (BTK) inhibitor.

NCT ID: NCT04035135 Completed - Clinical trials for Guillain-Barré Syndrome

A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

Start date: January 29, 2020
Phase: Phase 1
Study type: Interventional

This study is a multi center, open-label, study of ANX005 in combination with IVIg in subjects diagnosed with GBS.

NCT ID: NCT04034849 Completed - Clinical trials for Burning Mouth Syndrome

Effects of Photobiomodulation in Burning Mouth Syndrome

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

The main objective of this study is to assess the effects of Photobiomodulation with Low-level Laser Therapy to the pain management in Burning Mouth Syndrome patients, besides assessing their impact on the different aspects of their quality of life, using the necessary questionnaires to evaluate all the outcomes of chronic pain.

NCT ID: NCT04034316 Completed - Clinical trials for Nephrotic Syndrome in Children

Reduce Immunosuppression With Atmp in NS ChildrEn

RACE
Start date: November 2, 2018
Phase: Phase 2
Study type: Interventional

A phase II open-label, single arm study aimed to ascertain whether infusions of cord-blood mesenchymal stromal cells (CB-MSCs) allow to reduce or suspend the chronic immunosuppressive therapy (IS) in steroid-dependent nephrotic syndrome (SDNS). We plan to enroll 11 patients aged 3 to 18 with SDNS in remission for at least one month, maintained by either ≥2 immunosuppressive drugs or a calcineurin inhibitor. Patients are infused with cord-blood allogenic MSC, selected by in-vitro alloreactivity, at a dose of 1.5x10^6/kg on days 0, 14, 21. The immunosuppressive treatment is gradually tapered starting at the first CB-MSC administration, according to the following scheme: 25% following the first administration, 50% following the second administration, and 100% reduction following the third administration. All patients will be followed-up for 6 months from the last CB-MSC. Study visits are planned at baseline during CB-MSC administrations, 2 weeks (follow-up [FU]1) and 6 weeks (FU2) after the last infusion, and then every 6 weeks. During follow-up, the patients undergo a physical examination (including measurement of height, weight and blood pressure) and laboratory evaluations (urinary protein:urinary creatinine ratio, complete blood count, kidney function, plasma proteins, liver function, triglycerides and cholesterol). In addition, a blood sample is taken for regulatory T lymphocyte quantification, a marker of clinical response to the infusions.

NCT ID: NCT04032639 Recruiting - Clinical trials for Prader-Willi Syndrome

Stress and Brain Response Using MEG in PWS

Start date: May 30, 2019
Phase:
Study type: Observational

Individuals with Prader-Willi Syndrome (PWS) have increased hunger and food seeking behaviour, as well as learning (cognitive) challenges. In addition, some patients with PW been shown to have low cortisol production, particularly in stressful situations. However, research examining how hormonal, cognitive, and psychological factors are interrelated PWS is limited. To address this gap in knowledge, the goal of this project is to understand how changes in brain regions involved in controlling food intake and cognitive processes are related to changes in hormones regulating appetite, the stress hormone cortisol, and performance on neuropsychological tests.

NCT ID: NCT04031248 Completed - Clinical trials for Patello Femoral Syndrome

Whole Body Vibration and Exercise in Knee Pain

Start date: September 2, 2019
Phase: N/A
Study type: Interventional

The present study will consist of evaluating the effect of applying an exercise protocol on a vibratory platform in order to provoke immediate influences in the affected systems and in the quality of life of the patients with patella-femoral pain.

NCT ID: NCT04029805 Recruiting - Insulin Resistance Clinical Trials

Evaluation of a Combination of a Plant Extract and a Probiotic on Glucidic Metabolism in Women With PCOS and High Insulin Levels

Start date: May 29, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the present study is to evaluate the effect of the combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6 on parameters of the glucidic metabolism, anthropometric parameters, hormonal levels and the menstrual cycle in women with polycystic ovary syndrome and high insulin levels.